Holding GB:CURE?
Track your performance easily

GB:CURE Technical Analysis

Summary of all the Indicators

Summary
Buy
12Bullish
5Neutral
5Bearish
Oscillators
Buy
4Bullish
5Neutral
1Bearish
Moving Averages
Buy
8Bullish
0Neutral
4Bearish
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) Moving Averages Convergence Divergence (MACD) indicator is 0.15, suggesting VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD is a Sell.
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) 20-Day exponential moving average is 19.64, making it a Buy.
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) 50-Day exponential moving average is 19.43, making it a Buy.

VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD (CURE) Pivot Points

Jul 25, 2024, 03:50 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
19.98
19.98
19.98
19.98
19.98
19.98
19.98
Fibonacci
19.98
19.98
19.98
19.98
19.98
19.98
19.98

VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD (CURE) Moving Averages

Jul 25, 2024, 03:50 PM
Period
Simple
Exponential
MA5
19.74Sell
19.79Sell
MA10
19.90Sell
19.76Sell
MA20
19.56Buy
19.64Buy
MA50
19.41Buy
19.43Buy
MA100
19.25Buy
19.31Buy
MA200
18.92Buy
19.15Buy
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) 10-Day exponential moving average is 19.76, making it a Sell.
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) 100-Day exponential moving average is 19.31, making it a Buy.
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) 50-day simple moving average is 19.41, creating a Buy signal.
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) 100-day simple moving average is 19.25, creating a Buy signal.
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) 200-day simple moving average is 18.92, creating a Buy signal.

VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD (CURE) Technical Analysis

Jul 25, 2024, 03:50 PM
Name
Value
Action
RSI (14)
53.07
Neutral
STOCH (9,6)
43.98
Neutral
STOCHRSI (14)
58.77
Neutral
MACD (12,26)
0.15
Sell
ADX (14)
12.41
Buy
Williams %R
-45.01
Buy
CCI (14)
34.66
Neutral
ATR (14)
0.21
-
Ultimate Oscillator
52.94
Neutral
ROC
3.52
Buy
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) Relative Strength Index (RSI) is 53.07, creating a Neutral signal.
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) Trend Strength Indicator (ADX) is 12.41, creating a Buy signal.
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) Commodity Channel Index (CCI) is 34.66, creating a Neutral signal.
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s (CURE) Price Rate of Change (ROC) is 3.52, creating a Buy signal.

FAQ

Is CURE a Buy, Hold, or Sell?
Based on CURE’s technical indicators, CURE is a Buy.
    What is CURE’s RSI (14)?
    CURE’s RSI (14) is 53.07, which suggests CURE is a Neutral.
      What is CURE’s MACD?
      CURE’s MACD is 0.15, which suggests CURE is a Sell.
        What is CURE’s 5-day moving average?
        CURE’s 5-day moving average is 19.74, which suggests CURE is a Sell.
          What is CURE’s 20-day moving average?
          CURE 20-day moving average is 19.56, which suggests CURE is a Buy.
            What is CURE’s 50-day moving average?
            CURE’s 50-day moving average is 19.41, which suggests CURE is a Buy.
              What is CURE’s 200-day moving average?
              CURE’s 200-day moving average is 18.92, which suggests CURE is a Buy.
                What is CURE’s Williams % R (14)?
                CURE’s Williams % R (14) is -45.01, which suggests CURE is a Buy.
                  What is CURE’s CCI (14)?
                  CURE’s CCI (14) is 34.66, which suggests CURE is a Neutral.
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis